323 related articles for article (PubMed ID: 26045130)
1. Novel agents in mantle cell lymphoma.
Kumar A
Curr Oncol Rep; 2015 Aug; 17(8):34. PubMed ID: 26045130
[TBL] [Abstract][Full Text] [Related]
2. Are novel agents ready to assume the mantle in the frontline treatment of mantle cell lymphoma?
Yamshon S; Martin P
Clin Adv Hematol Oncol; 2021 Jun; 19(6):376-382. PubMed ID: 34106911
[TBL] [Abstract][Full Text] [Related]
3. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.
Arkwright R; Pham TM; Zonder JA; Dou QP
Expert Opin Drug Discov; 2017 Feb; 12(2):225-235. PubMed ID: 27917682
[TBL] [Abstract][Full Text] [Related]
4. Novel targeted therapeutics for mantle cell lymphoma--what's on the horizon?
El Halabi L; Ghez D; Ribrag V
Expert Rev Hematol; 2016 Mar; 9(3):271-81. PubMed ID: 26689790
[TBL] [Abstract][Full Text] [Related]
5. Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies.
Nastoupil LJ; Koff JL; Flowers CR
Oncology (Williston Park); 2013 Oct; 27 Suppl 2():8-12. PubMed ID: 25374999
[TBL] [Abstract][Full Text] [Related]
6. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
7. Current status of targeted therapies for mantle cell lymphoma.
Chang JE; Kahl BS
Drugs; 2011 Dec; 71(17):2307-26. PubMed ID: 22085387
[TBL] [Abstract][Full Text] [Related]
8. Emerging therapies in mantle cell lymphoma.
Hanel W; Epperla N
J Hematol Oncol; 2020 Jun; 13(1):79. PubMed ID: 32552760
[TBL] [Abstract][Full Text] [Related]
9. Treatment options for mantle cell lymphoma.
Smolewski P; Witkowska M; Robak T
Expert Opin Pharmacother; 2015; 16(16):2497-507. PubMed ID: 26360791
[TBL] [Abstract][Full Text] [Related]
10. Mantle cell lymphoma: the promise of new treatment options.
Goy A; Kahl B
Crit Rev Oncol Hematol; 2011 Oct; 80(1):69-86. PubMed ID: 21168343
[TBL] [Abstract][Full Text] [Related]
11. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.
Hess G; Smith SM; Berkenblit A; Coiffier B
Semin Oncol; 2009 Dec; 36 Suppl 3():S37-45. PubMed ID: 19963099
[TBL] [Abstract][Full Text] [Related]
12. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
Owen C; Berinstein NL; Christofides A; Sehn LH
Curr Oncol; 2019 Apr; 26(2):e233-e240. PubMed ID: 31043832
[TBL] [Abstract][Full Text] [Related]
13. High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.
Nabrinsky E; Danilov AV; Koller PB
Curr Hematol Malig Rep; 2021 Feb; 16(1):8-18. PubMed ID: 33507515
[TBL] [Abstract][Full Text] [Related]
14. Management of relapsed mantle cell lymphoma: still a treatment challenge.
Ruan J; Coleman M; Leonard JP
Oncology (Williston Park); 2009 Jul; 23(8):683-90. PubMed ID: 19711582
[TBL] [Abstract][Full Text] [Related]
15. Mantle cell lymphoma: insights into therapeutic targets at the preclinical level.
Klener P
Expert Opin Ther Targets; 2020 Oct; 24(10):1029-1045. PubMed ID: 32842810
[TBL] [Abstract][Full Text] [Related]
16. Mantle cell lymphoma in relapse: the role of emerging new drugs.
Diefenbach CS; O'Connor OA
Curr Opin Oncol; 2010 Sep; 22(5):419-23. PubMed ID: 20679769
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib in the treatment of mantle cell lymphoma.
Robak T
Future Oncol; 2015; 11(20):2807-18. PubMed ID: 26347482
[TBL] [Abstract][Full Text] [Related]
18. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
19. Mantle cell lymphoma-Advances in molecular biology, prognostication and treatment approaches.
Silkenstedt E; Dreyling M
Hematol Oncol; 2021 Jun; 39 Suppl 1():31-38. PubMed ID: 34105823
[TBL] [Abstract][Full Text] [Related]
20. Novel agents in mantle cell lymphoma.
Tucker D; Rule S
Expert Rev Anticancer Ther; 2017 Jun; 17(6):491-506. PubMed ID: 28480764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
